Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two years, it appears Moderna’s previous cost-cutting efforts haven’t g | ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read ...

Biotechnology company Moderna (NASDAQ:MRNA) announced better-than-expected revenue in Q2 CY2025, but sales fell by 41.1% year ...

Moderna also announced FDA approval for mNEXSPIKE® (mRNA-1283), a next-generation vaccine against COVID-19, for use in all adults aged 65 and older, as well as individuals aged 12-64 years with ...

Moderna expects to have mNEXSPIKE available for eligible populations in the U.S. also in the 2025-2026 respiratory virus season, alongside Spikevax.

The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of ...

HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...